Nanoparticle formation of organic compounds with retained biological activity

Journal of Pharmaceutical Sciences

Volumn 99, Issue 6, 2010, Pages 2750-2755

  Jacobson, Gunilla B ^a   Shinde, Rajesh ^b   McCullough, Rebecca L ^a   Cheng, Nicholas J ^a   Creasman, Adam ^b   Beyene, Amanuel ^a   Hickerson, Robyn P ^c   Quan, Can ^d   Turner, Charlotta ^d   Kaspar, Roger L ^c   Contag, Christopher H ^b   Zare, Richard N ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TransDerm Inc   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antioxidant; Biomaterials; Nanoparticles; Particle size; siRNA; Stability; Supercritical fluids

Indexed keywords

NANOPARTICLE; ORGANIC COMPOUND; QUERCETIN; SMALL INTERFERING RNA;

ARTICLE; BIODEGRADABILITY; BIOLOGICAL ACTIVITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; GENE SILENCING; PARTICLE SIZE; RNA INTERFERENCE;

EID: 77951525615     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22035     Document Type: Article

References (28)

1. Kesisoglou F, Panmai S, Wu Y. 2007. Nanosizing - Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 59: 631-644. (Pubitemid 47285408)
2. Rasenack N, Muller BW. 2004. Micron-size drug particles: Common and novel micronization techniques. Pharm Dev Technol 9:1-13. (Pubitemid 38258252)
3. Giry K, Péan JM. 2006. The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int J Pharm 321:162-166.
4. Xu CY, Sievers RE, Karst U, Watkins BA, Karbiwnyk CM, Andersen WC, Schaefer JD, Stoldt CR. 1998. Supercritical carbon dioxide assisted aerosolization for thin film deposition, fine powder generation, and drug delivery. In: Anastas PT, Williamson TC, editors. Green chemistry: Frontiers in benign chemical synthesis and processing. Oxford: Oxford University Press. pp. 312-334;4.;
5. Huang ETS, Chang H-Y, Liang CD, Sievers RE. 2003. Fine particle pharmaceutical manufacturing using dense carbon dioxide mixed with aqueous or alcoholic solutions. ACS Symp Ser 860:324-338.
6. Jung J, Perrut M. 2003. Particle design using supercritical fluids. J Supercrit Fluids 20:179-219;5.;
7. Knez Z, Weidner E. 2003. Particles formation and particle design using supercritical fluids. Curr Opin Solid State Mater Sci 7:353-361.
8. Ikariya T, Noyori R, Abrams MB, Carter CAG, Jacobson GB, Liu FC, Pesiri DR, Tumas W. 2000. Advances in homogeneous heterogeneous and biphasic metal-catalyzed reactions in dense-phase carbon dioxide. In: DeSimone J, Tumas W, editors. Green chemistry using liquid and supercritical carbon dioxide. New York: Oxford University Press. pp. 17-47.
9. Gupta RB, Chattopadhyay P. 2002. Method of forming nanoparticles and microparticles of controllable size using supercritical fluids and ultrasound. US Patent 20020000681.
10. Hanna MH, York P. 1998. Method and apparatus for the formation of particles. US Patent 5851453.
11. Erlund I. 2004. Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr Res 24:851-874;9.;
12. 9bFormica JV, Regelson W. 1995. Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol 33: 1061-1080.
13. Chebil L, Humeau C, Anthoni J, Dehez F, Engasser J-M, Ghoul M. 2007. Solubility of flavonoids in organic solvents. J Chem Eng Data 52:1552-1556.
14. Zheng Y, Haworth IS, Zuo Z, Chow MSS, Chow AHL. 2005. Physicochemical and structural characterization of quercetin-beta-cyclodextrin complexes. J Pharm Sci 94:1079-1089. (Pubitemid 40780774)
15. Gao Y, Wang Y, Ma Y, Yu A, Cai F, Shao W, Zhai G. 2009. Formulation optimization and in situ absorption in rat intestinal tract of quercetin-loaded microemulsion. Colloids Surfaces B 71:306-314.
16. Barras A, Mezzetti A, Richard A, Lazzaroni S, Roux S, Melnyk P. 2009. Formulation and characterization polyphenol-loaded lipid nanocapsules. Int J Pharm 379:270-277.
17. Brand-Williams W, Cuvelier ME, Berset C. 1995. Use of a free-radical method to evaluate antioxidant activity. Food Sci Technol-LEB 28:25-30.
18. de Fougerolles A, Vornlocher H-P, Maraganore J, Lieberman J. 2007. A progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6:443-453.
19. Novobrantseva TI, Akinc A, Borodovsky A, de Fougerolles A. 2008. Delivering silence: Advancements in developing siRNA therapeutics. Curr Opin Drug Discov Devel 11:217-224. (Pubitemid 351281061)
20. Hickerson RP, Vlassov AV, Wang Q, Leake D, Ilves H, Gonzalez-Gonzalez E, Contag CH, Johnston BH, Kaspar RL. 2008. Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides 18:345-354. (Pubitemid 352791342)
21. Hickerson RP, Smith FJD, Reeves RE, Contag CH, Leake D, Leachman SA, Milstone LM, Irwin McLean WH, Kaspar RL. 2008. Therapeutic siRNAs for dominant genetic skin disorder including pachyonychia congenita. J Invest Dermatol 128:594-605.
22. Jacobson GB, Lee CT Jr, Johnston KP, Tumas W. 1999. Enhanced catalyst reactivity and separation using water/carbon dioxide emulsions. J Am Chem Soc 121:11902-11903. (Pubitemid 30032777)
23. Berger JM, Rana RJ, Javeed H, Javeed I, Schulien SL. 2008. Radical quenching of 1,1-diphenyl-2-picrylhydrazyl: A spectrometric determination of antioxidant behavior. J Chem Edu 85:408-410;20.;
24. Sanchez-Moreno C, Larrauri JA, Saura-Calixto F. 1998. A procedure to measure the antiradical efficiency of polyphenols. J Sci Food Agric 76:270-276;20.;
25. Jimenez-Escrig A, Jimenez-Jimenez I, Sanchez-Moreno C, Saura-Calixto F. 2000. Evaluation of free radical scavenging of dietary carotenoids by the stable radical 2,2-diphenyl-1-picrylhydrazyl. J Sci Food Agric 80:1686-1690.
26. Leachman A, Hickerson RP, Hull PR, Smith FJD, Milstone LM, Lane EB, Bale SJ, Roop DR, McLean WHI, Kaspar RL. 2008. Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J Dermatol Sci 51:151-157.
27. Wiebe R, Gaddy VL. 1941. Vapor phase composition of carbon dioxide-water mixtures at various temperatures and at pressures to 700 atmospheres. J Am Chem Soc 63:475-477.
28. Novobrantseva TI, Akinc A, Borodovsky A, de Fougerolles A. 2008. Delivering silence: Advancements in developing siRNA therapeutics. Curr Opin Drug Discov Devel 11:217-224. (Pubitemid 351281061)